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Previous studies have reported less favorable outcome1–3 and less effect of endovascular treatment (EVT)4–8 after 
ischemic stroke among women compared with men. EVT 
was proven to be safe and effective in a meta-analysis of 5 
randomized controlled trials (RCTs) within the Highly Effective 
Reperfusion Using Multiple Endovascular Devices (HERMES) 
collaboration.7 As with the results of new and upcoming clin-
ical trials more patients seem to benefit from EVT, individu-
alized selection of patients for EVT has become of increased 
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effect of EVT for ischemic stroke in recent randomized trials on EVT.
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outcome was 90-day functional outcome (modified Rankin Scale). We compared baseline characteristics and outcomes 
between men and women. With ordinal logistic regression, we evaluated the association between EVT and 90-day 
functional outcome for men and women separately, adjusted for potential confounders. We tested for interaction 
between sex and EVT.
Results—We included 1762 patients in the analyses, of whom 833 (47%) were women. Women were older (median, 70 
versus 66 years; P<0.001), were smoking less often (30% versus 44%; P<0.001), and had higher collateral grades (grade 
3: 46% versus 35%; P<0.001) than men. Functional independence (modified Rankin Scale score, 0–2) at 90 days was 
reached by 318 women (39%) and 364 men (39%). The effect of EVT on the ordinal modified Rankin Scale was similar 
in women (adjusted common odds ratio [acOR], 2.13; 95% CI, 1.47–3.07) and men (acOR, 2.16; 95% CI, 1.59–2.96), 
with a P for interaction of 0.926.
Conclusions—Sex does not influence clinical outcome after EVT and does not modify treatment effect of EVT. Therefore, 
sex should not be a consideration in the selection of patients for EVT.   (Stroke. 2019;50:2413-2419. DOI: 10.1161/
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importance. This is best done by combining prognostic infor-
mation from multiple clinical and radiological characteristics.9 
However, uncertainty remains about the size of the treatment 
effect in specific subgroups, such as in women. In MR CLEAN 
(A Multicenter Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands), a 
significant interaction between sex and EVT was found.4 Men 
experienced a major benefit from EVT, whereas no significant 
treatment effect of EVT was found in women. The meta-analy-
sis of HERMES did not confirm these findings but did not fur-
ther elaborate on this topic, and baseline characteristics by sex 
were not reported.7 Since then, 2 more RCTs on EVT have been 
added to the HERMES collaboration data.10,11 We aimed to pro-
vide more insight on the influence of sex on outcome and on the 
effect of EVT for ischemic stroke in patient-pooled data of the 
7 RCTs within the HERMES collaboration.
Methods
Study Population and Design
We pooled the data from 1764 participants in the 7 RCTs on EVT 
within the HERMES collaboration (MR CLEAN,12 ESCAPE 
[Endovascular Treatment for Small Core and Anterior Circulation 
Proximal Occlusion With Emphasis on Minimizing CT to 
Recanalization Times],5 EXTEND-IA [Extending the Time for 
Thrombolysis in Emergency Neurological Deficits - Intra-Arterial],13 
SWIFT PRIME [Solitaire With the Intention for Thrombectomy as 
Primary Endovascular Treatment],6 REVASCAT [Randomized Trial 
of Revascularization With Solitaire FR Device Versus Best Medical 
Therapy in the Treatment of Acute Stroke due to Anterior Circulation 
Large Vessel Occlusion Presenting Within 8 Hours of Symptom 
Onset],14 THRACE [Mechanical Thrombectomy After Intravenous 
Alteplase Versus Alteplase Alone After Stroke],10 and PISTE [Pragmatic 
Ischaemic Stroke Thrombectomy Evaluation]11). These RCTs com-
pared EVT (intervention), primarily performed with stent retrievers, 
with standard care (control) in patients with an ischemic stroke caused 
by a large vessel occlusion in the anterior circulation. All participants 
provided informed consent according to each trial protocol, and each 
RCT was approved by the local ethics committee. The HERMES pro-
tocol and main outcomes have been reported previously.7,15 HERMES 
data are available via the VISTA-Endovascular repository.
Outcome Measures
The primary outcome was functional outcome, measured with the 
modified Rankin Scale (mRS) score, at 90 days. Secondary out-
comes were excellent 90-day functional outcome (mRS, 0–1), 
90-day functional independence (mRS, 0–2), extent of neurological 
deficits measured with the National Institutes of Health Stroke Scale 
(NIHSS) at 24 hours after randomization, successful reperfusion after 
EVT (modified Thrombolysis in Cerebral Infarction score ≥2B), and 
follow-up infarct volume (FIV) on noncontrast CT or magnetic reso-
nance imaging at 12 hours to 2 weeks. Safety outcomes were 90-day 
mortality and symptomatic intracranial hemorrhage, defined accord-
ing to each trial protocol.15
Statistical Analyses
Patients with missing data on sex were excluded from the analyses. 
We compared baseline characteristics and outcomes between men 
and women using descriptive statistics. With generalized linear mixed 
models, with trial as a random effect, we evaluated the association be-
tween EVT and primary and secondary outcomes. FIV was log trans-
formed (log+1) because of its skewed distribution, to best satisfy the 
linear model. We tested for interaction between sex and treatment al-
location using multiplicative interaction terms in the regression model. 
Regression analyses were adjusted for age, baseline NIHSS, time from 
onset to randomization, diabetes mellitus, prior stroke, occlusion lo-
cation, intravenous tPA (tissue-type plasminogen activator) admin-
istration, and collateral grade. Missing data in these covariates were 
imputed with simple imputation, with the exception of collateral grade 
(≥10% missing data), which was imputed with single imputation with 
regression based on relevant covariates, trial, and mRS. Unadjusted 
and adjusted common odds ratios and adjusted betas are reported with 
95% CIs, and all P are 2-sided. Statistical analyses were performed 
with SAS software, version 9.4, and R, version 3.3.
Results
After excluding 2 patients with unknown sex, we included 
1762 patients in the analyses, of whom 929 (53%) were men 
and 833 (47%) were women. Women were older (median, 
70 versus 66 years; P<0.001), were smoking less often (30% 
versus 44%; P<0.001), and had higher collateral grade (grade 
3: 46% versus 35%; P<0.001) than men (Table 1). There were 
no differences in medical history, especially atrial fibrillation, 
prestroke mRS, administration of tPA, and onset to randomi-
zation or groin puncture times between women and men.
The median 90-day mRS was the same for women and 
men in the intervention groups, and for women and men in 
the control groups, with significant differences between the 
intervention groups versus the control groups (4.0 versus 3.0; 
P<0.001; Table 2). Functional independence (mRS, 0–2) at 90 
days was reached by 318 women (39%) and 364 men (39%), 
with a similar distribution among the intervention and con-
trol groups, significantly in favor of the intervention group 
(Figure 1; Table 2). Mortality at 90 days was 15% for women 
and 16% for men. Mortality also did not differ between the in-
tervention and control group for both sexes. There was no dif-
ference between women and men in symptomatic intracranial 
hemorrhage (3.7% versus 3.6%) or in successful reperfusion 
(75% versus 76%). FIV was smaller in women (32 mL) than 
in men (53 mL; Table 2). FIV was also significantly smaller 
in the intervention group than in the control group in both 
women (27 versus 40 mL; P=0.009) and men (39 versus 70 
mL; P<0.001; Table 2), with an adjusted beta of −0.26 (95% 
CI, −0.49 to −0.02) and −0.33 (95% CI, −0.50 to −0.15; Table 
I in the online-only Data Supplement), respectively.
Treatment effect of EVT on the ordinal mRS was compa-
rable in women (adjusted common odds ratio, 2.13; 95% CI, 
1.47–3.07) and men (adjusted common odds ratio, 2.16; 95% 
CI, 1.59–2.96) with a P for interaction of 0.926 (Figure 2). 
Similarly, there was no difference between women and men 
in the effect of any of the additional secondary outcomes 
(Figure 2; Table I in the online-only Data Supplement).
Discussion
In this individual patient data meta-analysis that included 
1762 patients with ischemic stroke from multiple centers in 
multiple countries, treatment effects of EVT on functional 
outcome and other clinical, imaging, and safety outcome 
measures were similar in women and men.
To date, one study (MR CLEAN), which was also included 
in the current analysis, has previously addressed the same re-
search question.4 Contrary to the results of the present analysis, 
a significant interaction between sex and treatment effect in 
favor of men was found. Although in MR CLEAN, women had 
more unfavorable baseline characteristics, more serious adverse 
D
ow
nloaded from
 http://ahajournals.org by on November 27, 2019
Chalos et al  Interaction Between Sex and EVT in HERMES Data  2415
events, and higher mortality than men, a play of chance was 
suggested because these differences seemed to be insufficient 
to explain the lack of an overall treatment effect in women. A 
study on sex-based group differences in RCTs showed that sta-
tistically significant sex-treatment interactions are only slightly 
more frequent than what would be expected by chance.16 This 
underpins the idea that the significant sex-treatment interac-
tion observed in MR CLEAN was indeed a play of chance. 
Our results, which indicate that sex does not modify treatment 
effect of EVT in ischemic stroke, support previous findings 
of ESCAPE, EXTEND-IA, and HERMES, which all per-
formed a subgroup analysis by sex but did not report baseline 
characteristics and secondary analyses by sex, that there are 
no differences in treatment effect of EVT on functional out-
come between women and men.5–7 Our results are also in line 
with an analysis in patients with acute basilar artery occlusion, 
where no significant sex differences for outcome and recanali-
zation were observed, regardless of treatment with tPA (with or 
without EVT) or EVT alone.8 Also, several post hoc analyses 
based on pooled data from RCTs have shown that sex does not 
modify the treatment effect of tPA on clinical outcome.17–20
Clinical and safety outcomes also did not differ between 
women and men in the intervention group, which is similar to 
the findings of several previous studies that have assessed sex 
Table 1. Baseline Characteristics by Sex*
Characteristics Women (n=833) Men (n=929) P Value
Age, y 70 (58−77), 833 66 (57−74), 928 <0.001
Systolic blood pressure, mm Hg 145±26, 829 145±23, 924 0.945
Hypertension 58% (479/830) 55% (509/926) 0.248
Hyperlipidemia 36% (289/812) 40% (362/906) 0.065
Diabetes mellitus 16% (130/830) 17% (157/925) 0.477
Atrial fibrillation 34% (218/641) 32% (229/709) 0.524
Prior stroke 9.9% (82/829) 12% (106/921) 0.280
Smoking 30% (230/765) 44% (367/842) <0.001
Blood glucose, mg/dL 136±97, 596 130±43 (665) 0.142
NIHSS 17 (13−20), 826 17 (14−21), 925 0.027
Prestroke mRS 0.141
  0 81% (486/603) 84% (571/677)  
  1 14% (82/603) 12% (80/677)  
  ≥2 5.8% (35/603) 3.8% (26/677)  
ASPECTS 8.0 (7.0−9.0), 820 8.0 (7.0−9.0), 916 0.077
Intravenous tPA administration 89% (740/833) 90% (832/929) 0.645
Interhospital transfer 21% (177/830) 25% (234/926) 0.051
Occlusion location† 0.336
  ICA 26% (200/765) 27% (242/883)  
  M1 65% (497/765) 65% (576/883)  
  M2 8.6% (66/765) 7.4% (65/883)  
Collateral grade† <0.001
  0—absent collateral vessels 0.2% (1/599) 1.9% (13/691)  
  1—<50% filling of occluded area 13% (75/599) 18% (124/691)  
  2—>50% but <100% filling of 
occluded area
42% (249/599) 45% (309/691)  
  3—100% filling of occluded area 46% (274/599) 35% (245/691)  
Onset to randomization, min 182 (138−242), 831 184 (142−247), 924 0.289
Onset to tPA administration, min 120 (89−161), 736 115 (80−158), 828 0.117
Onset to groin puncture, min 240 (184−300), 369 238 (185−295), 415 0.670
ASPECTS indicates Alberta Stroke Program Early CT Score; ICA, internal carotid artery; IQR, interquartile range; M1, 
middle cerebral artery segment 1; M2, middle cerebral artery segment 2; mRS, modified Rankin Scale; NIHSS, National 
Institutes of Health Stroke Scale; and tPA, tissue-type plasminogen activator.
*Categorical variables are presented in percentage (n/N) and continuous variables in mean±SD, n, or median (IQR), n.
†Occlusion location and collateral grade: central reading.
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differences in functional outcome after EVT,21–23 with the ex-
ception of one study, which found that in patients treated with 
EVT, women were less likely to be independent at 90 days.24
Other studies, from before the implementation of EVT, 
have reported poorer stroke-related outcomes in women 
than in men, independently of treatment.1,3,25 However, in the 
Table 2. Outcome Measures for All Patients (Intervention+Control) by Sex, and by Sex and Treatment Allocation*
Outcome 
Measures
Intervention+Control Women Men
Women 
(N=833)
Men  
(N=929) P Value
Intervention 
(N=412)
Control  
(N=421) P Value
Intervention 
(N=459)
Control  
(N=470) P Value
Clinical outcomes
  mRS at 90 d 3.0  
(2.0−4.0), 820
3.0  
(2.0−4.0), 922
0.724 3.0  
(1.0−4.0), 408
4.0  
(2.0−5.0), 412
<0.001 3.0  
(1.0−4.0), 458
4.0  
(2.0−5.0), 464
<0.001
  mRS 0–1 at 
90 d
23% (190/820) 23% (210/922) 0.864 30% (121/408) 17% (69/412) <0.001 29% (133/458) 17% (77/464) <0.001
  mRS 0–2 at 
90 d
39% (318/820) 39% (364/922) 0.768 48% (195/408) 30% (123/412) <0.001 48% (219/458) 31% (145/464) <0.001
  NIHSS at 24 h 11  
(4.0−18), 796
12  
(5.0−18), 892
0.098 8.0  
(3.0−16), 393
14  
(7.0−19), 403
<0.001 9.0  
(4.0−17), 442
14  
(8.0−19), 450
<0.001
Imaging outcomes
  mTICI  
post-EVT†‡
0.383
   0 7.2% (25/346) 9.1% (35/383)       
   1 2.0% (7/346) 3.1% (12/383)        
   2A 16% (55/346) 12% (45/383)        
   2B 67% (231/346) 67% (256/383)        
   3 8.1% (28/346) 9.1% (35/383)        
  FIV at 12 h to 
2 wk, mL†
32 (12−99.5) 53 (15−141) <0.001 27 (11−91), 388 40 (16−106), 393 0.009 39 (12−120), 433 70 (21−155), 451 <0.001
Safety outcomes
  Mortality at 
90 d
15% (128/827) 16% (152/925) 0.602 16% (64/411) 15% (64/416) 1.000 14% (64/459) 19% (88/466) 0.051
  sICH 3.7% (30/817) 3.6% (33/910) 1.000 4.5% (18/404) 2.9% (12/413) 0.268 3.1% (14/448) 4.1% (19/462) 0.480
EVT indicates endovascular treatment; FIV, follow-up infarct volume; IQR, interquartile range; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral 
Infarction; NIHSS, National Institutes of Health Stroke Scale; and sICH, symptomatic intracranial hemorrhage.
*Categorical variables are presented in percentage (n/N) and continuous variables in median (IQR), n.
†mTICI post-EVT and FIV: central reading.
‡mTICI post-EVT only available for the intervention group.
Figure 1. Distribution of the modified Rankin 
Scale (mRS) score in percentages among the 
intervention and control group, for all patients 
and by sex. mRS was missing in 5 patients of 
the intervention group (4 women and 1 man) 
and in 15 patients of the control group (9 
women and 6 men).
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present study, 90-day functional independence and mortality 
were equal among women and men, also for those in the con-
trol groups only. An explanation for the difference between 
previous literature and our study may be selection, visible in 
the somewhat different baseline characteristics of women in 
our study compared with previous reports. In our study, for 
example, occurrence of atrial fibrillation was equal between 
women and men, while the prevalence of ischemic stroke 
caused by atrial fibrillation is usually higher in women.26 
Moreover, the NIHSS score at baseline was lower in women 
than in men and collateral grade was higher.
To the best of our knowledge, no research has been done 
on a possible association of sex with collateral grade, and not 
many studies have previously described baseline collateral 
grade by sex in patients eligible for EVT. The higher baseline 
collateral grade in women, which might be the result of se-
lection, is in line with the findings of an analysis done in MR 
CLEAN.27 In IMS III (Interventional Management of Stroke 
III Trial), which evaluated EVT+tPA versus tPA alone, no dif-
ference in collateral grade was found between women and 
men.28 As a higher collateral grade is associated with smaller 
FIVs after EVT,29–31 the smaller FIVs in women in our study 
might be correlated with the higher baseline collateral grade in 
women as well. However, this did not impact 90-day functional 
outcome in women. We think that the difference in FIV and in 
baseline collateral grade between men and women might not 
have been large enough explain a possible better outcome in 
women. Moreover, outcome is not dependent on FIV or base-
line collateral grade alone but on multiple variables (together), 
including age, prestroke disability, time, recanalization status, 
and notably the NIHSS score at 24 hours, which is a strong pre-
dictor of outcome and did not differ between women and men.
Women are often underrepresented in (stroke) clinical tri-
als. In the present study, women, eligible for EVT, were also 
less often included than men (47% versus 53%), even though 
more women than men experience a stroke in high-income 
countries,25 and large vessel occlusions (in the anterior circu-
lation) seem to occur more often in women than in men.32,33 
This may be the result of selection because clinical trials tend 
to select younger patients with lower baseline NIHSS scores. 
In a nonclinical trial setting, in 2 studies performed after the 
HERMES main results, 52% and 56% of all patients treated 
with EVT were women.23,24 Moreover, women seem to be less 
likely to receive any acute reperfusion therapy for (ischemic) 
stroke.34–36 This may be caused by various factors identified 
as being more common in women with ischemic stroke than 
in men, such as older age, higher prestroke disability, living 
alone, and higher occurrence of aphasia and reduced level of 
consciousness at presentation, which are also risk factors for 
late arrival.1,2,37,38 These factors could reduce the use of and 
access to acute reperfusion therapy in women. Future studies 
should focus on whether there are clinically relevant sex dif-
ferences in the incidence of large vessel occlusion and use of 
and access to EVT, which was also emphasized in a review on 
sex differences in ischemic stroke.39
A limitation of this study is the use of RCT data instead of 
data from more recent registries and surveys representing the 
current clinical practice. However, the use of RCT data made 
it possible to analyze potential differences in treatment effect 
of EVT between women and men and resolve the uncertainty 
that still existed about the treatment benefit of EVT in women. 
This would have been difficult, if not at all possible, if we had 
used observational data. Moreover, by using RCT data, we 
were able to control for numerous factors that were measured 
in a consistent, rigorous manner. Another limitation is lack of 
information about marital status. Marital status is known to 
be related to baseline sex differences, such as longer onset to 
randomization times (reflecting prehospital delays) in women, 
and could impact outcome.
We conclude that sex does not influence clinical outcome 
after EVT for ischemic stroke and that women and men ben-
efit equally from EVT. Sex should, therefore, not be a consid-
eration in the selection of patients for EVT.
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